These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 7589755

  • 1. GnRH analog administration in patients with polycystic ovarian disease.
    Meden-Vrtovec H.
    Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
    [Abstract] [Full Text] [Related]

  • 2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 3. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
    Filicori M, Campaniello E, Michelacci L, Pareschi A, Ferrari P, Bolelli G, Flamigni C.
    J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
    [Abstract] [Full Text] [Related]

  • 4. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI, Steingold KA, de Ziegler D, Lapolt PS, Chang RJ, Judd HL.
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [Abstract] [Full Text] [Related]

  • 5. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, Coniglione F, Sipione C, D'Agata R.
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [Abstract] [Full Text] [Related]

  • 6. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K, De Ziegler D, Cedars M, Meldrum DR, Lu JK, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [Abstract] [Full Text] [Related]

  • 7. The hormonal response of patients with polycystic ovarian disease to subcutaneous low frequency pulsatile administration of luteinizing hormone-releasing hormone.
    Hurwitz A, Rosenn B, Palti Z, Ebstein B, Har-Nir R, Ron M.
    Fertil Steril; 1986 Sep; 46(3):378-84. PubMed ID: 2943606
    [Abstract] [Full Text] [Related]

  • 8. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP, Laven JS, Mulders AG, Oberyé JJ, Mannaerts BM, de Jong FH, Fauser BC.
    J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
    [Abstract] [Full Text] [Related]

  • 9. Acute ovarian responses to a long-acting agonist of gonadotropin-releasing hormone in ovulatory women and women with polycystic ovarian disease.
    DeFazio J, Meldrum DR, Lu JK, Vale WW, Rivier JE, Judd HL, Chang RJ.
    Fertil Steril; 1985 Oct; 44(4):453-9. PubMed ID: 3932097
    [Abstract] [Full Text] [Related]

  • 10. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR, Aceto T, Weber C, Pang S.
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [Abstract] [Full Text] [Related]

  • 11. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ, Laufer LR, Meldrum DR, DeFazio J, Lu JK, Vale WW, Rivier JE, Judd HL.
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [Abstract] [Full Text] [Related]

  • 12. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
    Cheung AP, Lu JK, Chang RJ.
    Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
    [Abstract] [Full Text] [Related]

  • 13. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
    Christman GM, Randolph JF, Kelch RP, Marshall JC.
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
    Taskin O, Yalcinoglu AI, Kafkasli A, Burak F, Ozekici U.
    Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
    [Abstract] [Full Text] [Related]

  • 15. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Spina MA, Apa R, Menini E, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [Abstract] [Full Text] [Related]

  • 16. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC, Pache TD, Lamberts SW, Hop WC, de Jong FH, Dahl KD.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory actions of a gonadotropin-releasing hormone agonist on ovarian follicle-stimulating hormone receptors and adenylate cyclase in vivo.
    Ranta T, Baukal A, Knecht M, Korhonen M, Catt KJ.
    Endocrinology; 1983 Mar; 112(3):956-64. PubMed ID: 6295748
    [Abstract] [Full Text] [Related]

  • 18. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
    Lubin V, Charbonnel B, Bouchard P.
    Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
    [Abstract] [Full Text] [Related]

  • 19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [Abstract] [Full Text] [Related]

  • 20. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.